Rearrangement of the tal-l gene (also known as SCL or TCL-5) occurs in at least 25% of T-cell acute lymphoblastic leukemias (T-ALLs) and results in the aberrant expression of tal-l mRNA in the neoplastic cells. Also, tal-l mRNA is constitutively expressed in erythroid precursors and megakaryocytes. This report describes a direct immunocytochemical study of the distribution and localization of TAL-l protein in normal human tissues and cell lines using four monoclonal antibodies raised against recombinant TAL-l proteins. One of these reagents recognizes a protein of 41 kD molecular weight in in vitro-translated TAL-l proteins, two others recognize proteins of 39 and 41 kD molecular weight, and the fourth antibody also recognizes a TAL-l protein of 22 kD in addition to the 39-and 41-kD proteins. These anti-TAL-l
antibodies label the nuclei of erythroid precursor cells and megakaryocytes in fetal liver and adult bone marrow. The punctate pattern of nuclear labeling suggests that TAL-l may comprise part of a novel nuclear structure, similar to that recently found for the PML protein. The nuclei of T cell lines known t o express mRNA encoding the full-length TAL-1 protein (eg, CCRF-CEM, RPM1 8402, and Jurkat) are also labeled. A study of normal human tissues (including thymus) showed labeling of smooth muscle, some tissue macrophages, and endothelial cells. TAL-l protein is undetectable in other cell types. These reagents may play an important role in the diagnosis of T-ALL and could also be used in the context of lymphoma diagnosis on routinely fixed material. that TAL-1 protein is likely to be modulated by extracellular stimuli.
Expression of tal-l mRNA in cell lines and tissues has been studied in a number of laboratories by Northern blot analysis, by polymerase chain reaction (PCR), and by in situ hybridization. Studies have found tal-l mRNA to be present at high levels in cells of the erythroid, megakaryocytic and mastocytic lineages and at low levels in some B and early myeloid cell lines.'~9~''*25*26 It has also been found in endothelial cells, notably in blood vessels in the ~pleen. 2~ While these studies provide a strong clue as to which cells are likely to contain the TAL-l proteins, they throw no light on the subcellular localization of this protein. In addition, they do not take into account factors that may influence the level and pattern of TAL-l protein expression in individual cells. For example, bcl-2 mRNA, but not BCL-2 protein expression, has been found in germinal center cells and epithelium, indicating that the bcl-2 gene expression may be controlled at a posttranscriptional The reverse situation has been described in the case of myeloid granule proteins. Neutrophil elastase can be found in high levels in mature granulocytes whereas its mRNA is no longer detectable in cells after the myelocyte stage. 30 There is, therefore, a requirement for direct immunocytochemical studies of TAL-l protein expression in human tis- sues. We report the characterization of four murine monoclonal antibodies directed against the human TAL-l protein, which have enabled us to study the pattern of TAL-l protein expression directly in cell lines and in normal human tissues.
MATERIALS AND METHODS
Generation of recombinant pGEX plasmids. Glutathione Stransferase (GST)-TAL-I Exo8D fusion protein (A) was created by the insertion of tal-/ nucleotides encoding amino acids 3 to 331 into the pGEX-3X vector (Pharmacia, Uppsala, Sweden) between the BamHI and EcoRI sites, in frame with GST (Fig 1) . This fusion protein construct uses the tal-l stop codon.
The smaller GST-TAL-l bHLH (B) (amino acids 172-289) fusion protein was generated by PCR from the 1.3-kb Pst I fragment of tal-I cDNA4 cloned in pGEM-3 using the N-terminal primer 5'-GAggaTCCCCCTATGAGATGGAGATT-3' together with the universal primer. The PCR product was digested by BumHI and Pvu IT and ligated in frame into the BamHI-Sma I site of the pGEX-2T vector (Pharmacia). The GST-TAL-I bHLH construct uses the pGEX-2T stop codon downstream of the EcoRI site. The authenticity of both constructs was verified by sequencing.
Pur8cation of GST-TAL-I proteins from Escherichia coli. GST fusion protein expression and purification were performed essentially as described by Smith and Johnson.3' Overnight cultures of E coli (UT 5600), transformed with either pGEX-2T or pGEX recombinants, were diluted 1/10 in NZCYM medium with ampicillin (100 pg/mL; GIBCO BRL, Eragny, France) and incubated at 37°C. After 4 hours of growth, isopropyl-P-D-thiogalactopyranoside (IPTG; Sigma Chemical CO, Poole, Dorset, UK) was added at a final concentration of 0.4 mmol/L, and the cultures were incubated for 1 hour at 25°C. The bacterial cultures were pelleted by centrifugation at 5,OOOg for 5 minutes at 4°C and resuspended in 1/10 volume of NTEN (20 mmol/L Tris, pH 8.0; 100 mmollL NaCI; 1 mmol/L EDTA; 0.5% NP40). The bacteria were then lysed by sonication and centrifuged at 10,OOOg for 10 minutes at 4°C. An aliquot of 80 pL of glutathione-Sepharose 4B (1 : 1 vollvol in NTEN; Pharmacia) was added to each milliliter of the bacterial supernatant, and the suspension was gently rocked for 30 minutes at 4°C. The glutathioneSepharose beads 4B were then washed three times with NTEN. The GST and GST-fusion proteins were eluted with 15 mmollL of reduced glutathione (Sigma) in 50 mmol/L Tris-HCI, pH 8.0. After repeated dialysis against phosphate-buffered saline (PBS), aliquots of the eluted proteins were analyzed on sodium dodecyl sulfate (SDS)-polyacrylamide gels and visualized by Coomassie Blue staining.
Production of antibodies. Balb/c mice were injected three times intraperitoneally at 8-day intervals with 25 pg of both the full-length GST-TAL-l Exo8D recombinant protein and the shorter GST-TAL-l bHLH recombinant protein, emulsified in Freund's adjuvant. Three days after a fourth intravenous injection (without adjuvant), a fusion was performed as described by Pulford et Serum was collected from the mouse. Initial screening was performed against GST and against both the shorter and longer length TAL-l recombinant proteins using an enzyme-linked immunosorbent assay (ELISA) technique (see below). Further screening was performed on cryostat sections of normal tonsil and on cytocentrifuge preparations of the K562 and Raji cell lines.
Preparation of cell and tissue samples. Normal peripheral blood mononuclear cells were separated on Lymphoprep (Nyegaard, Oslo, Norway), and cytocentrifuge preparations were made. Heparinized leukemic peripheral blood and bone marrow samples were obtained from patients attending the John Radcliffe Hospital, Oxford, UK. These samples were used to prepare blood smears or cytocentrifuge preparations. All slides were fixed and stored as previously described. Construction of tal-l expression plasmid and transfections. To produce the tal-/ expression vector pcDNA-tal-SI, full coding sequences contained in a 1.3-kb Pst I fragment were excised from the pGEM blue plasmid (Promega Biotech, Madison, WI) by HindIIIEcoRI digestion and cloned into the corresponding sites of pcDNA Neo wt, a eukaryotic expression vector with a CMV promoter (In Vitrogen, San Diego, CA). For stable transfections, the pcDNA-tal-S1 and the pcDNA Neo wt expression vectors were linearized by Stu I and Sst 11, respectively.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From HeLa cells (IO') were added to a mixture of either 9 pg of pcDNAral-SI and 1 pg of pcDNA Ne0 wt, or with only 10 pg of pcDNA Ne0 wt alone in 250 pL PBS-HEPES, and were then subjected to electroporation (250 V, 960 pF) in a Gene Pulser apparatus (Biorad Laboratories, Hemel Hempstead, UK). Cells were then cultured in ReMI 1640 with 10% fetal calf serum at 37°C in 5% CO,. After 48 hours, selection was initiated by the addition of 750 p g / d of G418 (Geneticin; GIBCO BRL, Paisley, Scotland) to the culture medium. Individual colonies were picked under an inverted microscope 10 to 12 days after plating, and these transfected cells were expanded and maintained in culture. Cytocentrifuge preparations of these cells were then made.
Source of monoclonal antibodies. Antibodies to CD3, CD13, CD19, CD33, CD34, CD61, vimentin (V9), and cytokeratin (LP34) were obtained from Dako d s (Glostrup, Denmark). Antibodies to CD2, CD45, CD68, CD71, glycophorin A, and rabbit Ig (MR12) were produced in one of the investigator's laboratories (K.P., D.Y.M.).
ELISA. Fifty microliters of a 5 pg/mL solution of GST, GST-TAL-l ExolD, or GST-TAL-I bHLH was added to each well of a Maxistrip microtiter plate (GIBCO Biocult Ltd, Paisley, Scotland). After 2 hours at room temperature, the plates were washed in PBS containing 0.1% bovine serum albumin (BSA) and 0.1% Tween 20 (Sigma). Free protein-binding sites on the plates were blocked with PBS containing 0.5% BSA and 0. I % Tween 20 for a further 2 hours at 37°C. Then 50 pL of hybridoma supernatant were added to each well for 30 minutes. After a wash, 50 pL of peroxidase-conjugated goat-antimouse Ig (Dako ds) was then added. After 30 minutes and a final wash in distilled water, the reaction was developed using the soluble substrate 2,2'-azino-di-(3-ethylbenzthiazoline sulfonic acid) (Sigma). supernatants that reacted with the recombinant fusion proteins but not with GST were selected for further study.
Immunocytochemical staining. The immunoperoxidase technique was performed using either a t~o-stage'~ or a modified streptavidin-biotin three-~tage'~ technique. For the two-stage procedure, the slide preparations were incubated with a monoclonal antibody for 30 minutes. After washing in TBS (0.5 m o m Tris HCI, pH 7.6, diluted 1:lO with 1.5 m o m saline), the slides were incubated with peroxidase-conjugated goat-anti-mouse Ig (Dako d s ) . For the threestage staining process, slides were incubated with a monoclonal antibody for 30 minutes. The slides were then washed in TBS and incubated for 30 minutes with a biotin-conjugated goat-antimouse Ig (Dako ais) before being washed and incubated for a further 30 minutes with a streptavidisolution (Dako ds). The peroxidase reaction was developed using diaminobenzidine tetrahydrochloride (DAB; Sigma) and hydrogen peroxide. In some cases, 10 mg nickel chloride was added to the DAB mixture to enhance the intensity of the reaction product. The slides were then either directly mounted in Apathy's mountant (BDH, Lutterworth, UK) or weakly counterstained with hematoxylin before mounting. Where necessary, endogenous biotin was blocked by preincubating the cells or tissues with 0.1% solution of avidin in TBS for 20 minutes, followed by incubation in a 1% solution of biotin (Sigma) in TBS for 20 minutes before the staining procedure was performed. Formalin-fixed slides were dewaxed and rehydrated before the staining procedure.
For double-labeling, immunoperoxidase staining was first performed (as described above), and then the alkaline phosphatase:antialkaline phosphatase (APAAP) staining procedure was perf~rmed.~' The APAAP reaction was visualized using napththol AS-MX phosphate and Fast Red (TR-Salt) substrates (Sigma) as previously described?'," FACS staining. K562, HEL, CCRF-CEM, and Daudi cells were permeabilized using buffered formol acetone (BFA) as described by Slaper-Cortenbach et al.' * The cells were then washed in PBS containing 0.1% BSA and incubated for 30 minutes at 4°C with a monoclonal antibody, washed again, and then incubated for 30 minutes with fluorescein isothiocyanate (FITC)-conjugated F(ab'), rabbit-antimouse Ig (Dako ah). Antivimentin antibody, V9, was used to confirm that more than 95% of the cells had been permeabilized. After a final wash, the cells were fixed in 1.5% formaldehyde in PBS and analyzed in a FACScan flow cytometer (Becton Dickinson, Oxford, UK) using Consort 30 software. In some experiments the cells were not permeabilized before labeling in order to detect the presence of surface antigens.
In vitro transcription-translationandimmunoprecipitation. Templates for in vitro transcription consisted of either a 1.3-kb Pst I fragment that contains full tal-I coding sequences or a 0.9-kb EcoRIBamHI fragment encoding the 22-kD protein4 cloned into the pGEM-3 plasmid. RNA was synthesized from linearized plasmid DNA templates using T7 RNA polymerase (Promega). Synthesized RNA (I pg) was translated in vitro using a nuclease-treated rabbit reticulocyte lysate in the presence of "S methionine (Amersham, Amersham, UK) under the conditions recommended by the manufacturer (Promega).
For each immunoprecipitation, 10 pL of the reticulocyte lysate containing methionine-labeled TAL-1 proteins were diluted with 300 pL of NET-gel buffer (50 mmom Tris-HC1, pH 7.5; 150 mmoV L NaCl; 0.1% Nonidet P 4 0 (NP-40); 1 mmoYL EDTA, pH 8.0; 0.25% gelatine; and 0.02% sodium azide) and mixed with 100 pL of undiluted hybridoma tissue culture medium for 2 hours at 4°C. Antimouse Ig (1 pL) was added for 1 hour. Eighty microliters of Protein-A Sepharose (Pharmacia) beads was then added, and the mixture was rocked gently for a further hour. The beads were washed twice with NET-gel buffer and twice with immune buffer (50 m o l / L Tris-HC1, pH 7.5; 150 mmol/L NaCI; 0.5% N P -4 0 ; 0.5% sodium deoxycholate; 1 mmom EDTA, pH 8.0 and 0.02% sodium azide).
Finally, the antigen-antibody complexes were eluted from the beads by the addition of 2 x sample buffer (0.1 m o m Tris-HC1, pH 6.8; 2% SDS; 40% glycerol; 10 mmoVL EDTA; 0.004% bromophenol blue), boiled for 3 minutes, and run on a 12% SDS-polyacrylamide
The gel was then dried and exposed to x-ray film.
RESULTS

ELISA.
Two fusions were performed. The initial screening of hybridoma Supernatants was performed using an ELISA. Only those reagents reacting with the full-length TAL-l fusion protein GST-TAL-1 Exo8D andlor the shorter-length GST-TAL-l bHLH but not with the GST were selected. Three supernatants recognizing only the full-length TAL 1 fusion protein were produced in the first fusion. A fourth supernatant, obtained from the second fusion, recognized both the TAL1 Exo8D and the shorter TAL-l bHLH fusion proteins. These four Supernatants were analyzed further.
Western blotting. Secondary screening was performed by Western blotting analysis using total extracts prepared from E coli cultures expressing one of the following fusion proteins: GST-TAL-1 Exo8D, GST-TAL-1 bHLH or GST-LYL bHLH (data not shown). None of the four supernatants reacted with the fusion protein GST-LYL bHLH. Three supernatants recognizing only the GST-TAL-l Exo8D were cloned by limiting dilution to produce the monoclonal antibodies 2TL75,2TL170, and 2TL242. The fourth supernatant, raised in the second fusion, recognized both the GST-TAL-1 Exo8D and the GST-TAL-1 bHLH fusion proteins and was cloned to produce the monoclonal antibody BTL73.
Immunoprecipitation. The specificity of the four monoclonal antibodies was then confirmed by immunoprecipita- PULFORD ET AL tion of TAL-l proteins produced by in vitro translation in a rabbit reticulocyte lysate (Fig 2) . Using the full length tal-I mRNA, three major polypeptides of 41 kD, 39 kD, and 22 kD (lane A) were produced that correspond respectively to the initiation of translation at the first. second, and fifth ATG, as already described: All of these three proteins were clearly immunoprecipitated by the hyperimmune mouse sera; whereas no TAL-l proteins were recognized by the mouse preimmune sera (data not shown Analysis of a series of hematopoietic cell lines, summarized in Table 1 , showed variation of TAL-l labeling that correlated with the amount of tal-! mRNA reported to be present in these cells. With the exception of the cell line DU.528, all four anti-TAL-l reagents gave nuclear labeling in those lines that expressed tal-l mRNA.
Intense staining was seen with the HEL (Fig 3a) and K562 cell lines. The amount of labeling varied from cell to cell. In some cells, a discrete punctate nuclear labeling waq observed (Fig 3a and b) . In contrast, punctate cytoplasmic labeling but not nuclear labeling was observed in mitotic cells or in those For personal use only. on September 24, 2017. by guest www.bloodjournal.org From cells that had the appearance of just having undergone mitosis (Fig 3d) . None of the antibodies stained the nucleoli of the cells. A small population of cells showed labeling of small ring-like or toroidal structures in the nuclei (Fig 3e) . The antibodies also labeled the nuclei of the T-lymphoblastic cell lines Jurkat, CCRF-CEM, and RPM1 8402 (Fig  3f) . Labeling in these preparations was not as intense as that seen in the K562 and HEL cell lines. The antibodies 2TL75, 2TL170, and 2TL242 produced only weak punctate-labeling of the cytoplasm of the DU.528 cell line (Fig 3g) . However, antibody BTL73 gave strong nuclear labeling of the DU.528 cells (Fig 3h) . Antibodies 2TL75 and 2TL242 gave weak labeling of a dot-like structure in the cytoplasm of the Raji B cell lines.
All of the antibodies gave strong labeling of the nuclei of a population of HeLa cells that had been transfected with pcDNA-tal-S1 (Fig 3i) . As found in other TAL-l-positive cell lines, the intensity of staining varied from cell to cell, and cytoplasmic labeling was observed in mitotic cells. No staining was seen of HeLa cells that had been transfected with pcDNA Neo wt (Fig 3i, insert) . These results with the transfected cells provide further confirmation of the specificity of the antibodies 2TL75, 2TL170, and 2TL242 for the TAL-1 protein.
All other T, B, myeloid, and nonhernatopoietic cell lines tested were not stained by the anti-TAL-l reagents.
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Immunocytochemical studies on normal hematopoietic cells and tissue. The results are summarized in Table 2 . All four antibodies labeled the nuclei of erythroid cells in cryostat sections of fetal liver (Fig 4a) . Double-labeling studies showed that the TAL-l-positive cells possessed either antigens known to be present on erythroid precursors, namely, CD71, the transferrin receptor [Fig 4b) , and glycophorin A (Fig 4c) , or the megakaryocyte marker CD61 (Fig  4d) . A subpopulation of TAL-l -positive cells lacking glycophorin A was also seen (Fig 4c) . This finding indicated that the latter antigen is not found in earlier erythroid precursor cells. None of the anti-TAL-l reagents labeled hematopoietic cells expressing the CD2, CD33, CD34, or CD45 antigens, or hepatocytes (Fig 4e) .
Two of the antibodies (2TL75 and 2TL242) stained erythroid and megakaryocytic cells in paraffin-embedded sections of formalin-fixed fetal liver.
All four antibodies labeled erythroid precursors and megakaryocytes in cytocentrifuge preparations of adult bone marrow. The identity of these cells was confirmed by double labeling (Fig 5) . As found in the fetal liver, there was a small population of cells with large nuclei that were labeled for TAL-l protein and transferrin receptor (CD71) but not for glycophorin A (Fig 5b) . No labeling of monocytes, neutrophils, or lymphoid cells was seen.
Immunocytochemical studies on normal nonhematopoietic tissue. The results (summarized in Table 2 ) showed clear, if minor, differences between the reactions of all four antibodies. Antibody 2TL170 appeared to be the most restricted in its reactivity, weakly labeling the nuclei of a subpopulation of endothelial cells in larger vessels in tonsil (Fig 6) and spleen but no other cell types. The two antibodies 2TL75 and 2TL242 resembled antibody 2TL170 by labeling endothelial cells in the tonsil and spleen, but they also stained some endothelial cells in thymus, placenta, and kidney. In addition, they gave weak nuclear labeling of macrophages in the lung and a few scattered macrophages in the tonsil, kidney, and cerebellum. They both labeled the luminal margin of splenic sinusoidal lining cells and smooth muscle in the uterus. Antibody BTL73 appeared to show an intermediate pattern of reactivity.
Flow cytometric analysis. The anti-TAL-l reagents labeled the permeabilized HEL, K562, and CCRF-CEM cell lines (Fig 7) . The intensity of labeling varied between the cell lines but correlated with the degree of staining seen in cytocentrifuge preparations. No staining was seen of the Daudi (B-cell) line. None of the anti-TAL antibodies labeled the surface of any of the cell lines studied.
DISCUSSION
In the past, the tissue and cellular localization of TAL-1 protein in human tissues has been inferred from its pattern of mRNA The recent immunocytochemical study by Kallianpur et a14' using polyclonal antisera has confirmed the presence of TAL-l protein in murine erythroid, megakaryocytic, and endothelial cells. This report, however, describes the first study of the distribution and localization of TAL-l protein in normal human tissues and cell lines performed using monoclonal antibodies.
For The rul-I gene is composed of at least 8 exons that, from their nucleotide sequence, were predicted to encode two major proteins of approximately 34 and 22 kD molecular weight, both of which express the bHLH regi0n.4.'~ The Western blotting studies, using polyclonal antibodies raised against TAL-l recombinant protein, have confirmed the presence of TAL-l protein of 37 to 42 kD and 22 to 24 kD molecular weight in tal-I-transfected COS cells" and in erythroid and T cell
The antibodies described in this report also recognize molecules of similar molecular weight, namely, 41, 39, and 22 kD, in in vitro-translated TAL-1 protein preparations. Interestingly, the antibody 212170 was able to react with only the 41 -kD and not with the 39-kD protein. As the 41-kD species differs from the 39-kD species only by the presence of the first 25 N H z terminus residues: our data suggest that antibody 2TL170 recognizes an epitope located in the extreme amino terminus of the TAL-l protein. The monoclonal antibodies 2TL75 and 2TL242 were able to precipitate both the 39-and 41-kD species but not the smaller 22-kD protein, indicating that the epitopes recognized by these two antibodies are located in the segment of TAL-l protein between the residues Met 26 and Met 176.4 As antibody BTL73 recognized all three in vitro-translated proteins, its epitope probably lies at the carboxyl terminus of the TAL-l protein.
All four monoclonal antibodies labeled the nuclei of the K562 and HEL cell lines and also the nuclei of erythroid and megakaryocytic cells (in normal fetal liver and bone marrow). Kallianpur et al" using polyclonal antisera also found evidence for TAL-1 protein in erythroblasts and megakaryocytes in the mouse. These results are in close agreement with those of previous investigators who showed that tal-I mRNA expression is a feature of erythroid and megakaryocytic differentiation in both human and mouse tissues and cell
The presence of TAL-l protein in these hematopoietic cells suggests that it may play a role in their differentiation and t u r n~v e r ? . " * '~.~" '~~ evidence that the tal-l gene is a target for the GATA-1 transcription factor, and the resulting TAL-l protein may act as a positive regulator of erythroid differentiation.
Investigators have found tal-l mRNA in the Jurkat, CCRF-CEM, and RPM1 8402 T cell
The presence of the TAL-l protein in these cell lines was confirmed in the present study. Although DU.528 cells do express tal-l mRNA, this cell line is associated with a t(1; 14) translocation affecting the 3' region of the tal-] gene.'" In this situation, transcription is initiated at a cryptic promoter located within exon 4, and the resulting tal-l mRNA encodes only the 22-kD TAL-l protein, and the transcript for the fulllength TAL-l protein is absent.& This accounts for the presence of nuclear labeling in this cell line, using antibody BTL73 only. In vitro studies indicate that the dot-like pattern of cytoplasmic staining of the DU.528 and Raji cell lines seen using two of the antibodies (2TL75 and 2TL242) may be caused by crossreactivity of these antibodies with a cyto- Kallianpur et a14' found evidence of TAL-l protein in macrophages in murine bone marrow using polyclonal anti-TAL-1 sera. In the present study, although the monoclonal antibodies 2TL75 and 2TL242, and to a lesser extent antibody BTL73, stained macrophage nuclei weakly in the lung, kidney and brain, no labeling was seen of any macrophages in the bone marrow. Therefore, we hesitate to make any definitive claim for TAL-l expression in the human mononuclear phagocyte lineage.
In the present study, we were unable to detect the presence of any TAL-l proteins in thymocytes or in CDZpositive PULFORD ET AL lymphoid cells in the fetal liver. This is consistent with the absence of tal-] transcription previously found in these tisHowever, using the very sensitive method of reverse transcriptase-PCR, Mouthon et a12' did detect faint tal-l transcription in human thymus. More recently, Kallianpur et a14" showed the presence of TAL-l proteins in some murine thymic hematopoietic cells. Both these sets of data suggest that only a very small population of thymocytes may express TAL-l. These findings do not allow us to conclude whether tal-l plays a physiologic role in early human lymphoid differentiation.
It is clearly of interest to know if TAL-l protein is found in nonhematopoietic cells. In a recent study, Hwang et al" showed the presence of tal-l mRNA in the larger blood vessels of the spleen. Kallianpur et a14' also found TAL-l protein in endothelial progenitors, as well as in differentiating endothelia in the mouse. These findings, together with those obtained in the present study in which all four anti-TAL-l monoclonal antibodies labeled the nuclei and cytoplasm of a subpopulation of endothelial cells, provide further evidence for the expression of TAL-1 protein in human endothelium. Three of the monoclonal antibodies also labeled smooth muscle in the present study. This is also in agreement with the presence of TAL-l found in murine smooth mu~cle.~"
In the present study, all nuclei that were labeled by the anti-TAL-l antibodies showed no reactivity of the nucleolus. This pattern of staining was seen by Goldfarb et all9 using polyclonal anti-TAL-l reagents to stain cells transfected with the tal-l gene. A nuclear, rather than cytosues~4.9.11.14.42 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From plasmic, localization of the TAL-l protein is in keeping with the presence of an HLH region with a basic domain within the TAL-l protein.Ig The punctate pattern of labeling with some looped or toroidal structures visible in the nuclei observed in the present study was reminiscent of the appearance of DNA replication forks at sites of DNA synthesis demonstrated by Leonhardt et aL4' This labeling pattern is also similar to the novel nuclear domains recently identified by Dyck et a14' and Weis et a149 in studies of the retinoic acid receptor. Further studies of the subnuclear localization of the TAL-l protein are currently in progress.
U
The cytoplasmic labeling for TAL-l seen in mitotic cells or in immediately postmitotic cells suggests that TAL-l protein may leave the nucleus during the mitotic cycle. Goldfarb et all9 and Cheng et a120*22 have provided evidence that TAL-1 protein can undergo phosphorylation, and it is known that DNA binding of other bHLH transcription factors (Max and myogenin) can be inhibited when they are phosphorylated.5@5z Therefore, phosphorylation of the TAL-l protein might result in its relocation to the cytoplasm during mitosis.
Human and mouse TAL-l proteins share a high degree of h~mology.'~ However, at present we have no evidence to suggest that the monoclonal antibodies described here recognize murine TAL-l proteins.
In conclusion, monoclonal antibody 2TL170, raised against recombinant TAL-1 protein and recognizing only the 41-kD protein, shows a pattern of localization of the TAL-1 protein that corresponds closely with that predicted by previous studies of tal-l mRNA. Antibodies 2TL75 and 2TL242, recognizing the 39-and 41-kD proteins, together with antibody BTL73, recognizing an additional TAL-l protein of 22 k D , also demonstrated similar labeling to that seen with antibody 2TL170. However, these reagents also labeled some macrophages and some nonhematopoietic cells. Although the results obtained with these antibodies may be caused by crossreactivity with other antigens, the results could reflect the true tissue distribution of the 22-kD and 39-kD TAL-1 proteins. Additional studies, using polyclonal or other monoclonal antibodies, are required to address this problem further.
An important practical implication of the present study is that TAL-l protein, when present in the cell nucleus at sufficiently high levels to be detected by immunocytochemical techniques, may form the basis of a diagnostic test in Tcell lymphoblastic leukemia. We are currently in the process of analyzing a series of such cases to examine this possibility further.
